Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDCT in Lumbar Intervertebral Disc Degeneration
NCT07254806Phase 3Recruiting
- Sponsor
- DiscGenics
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of rebonuputemcel in degenerative disc disease (DDD), sponsored by DiscGenics. Started Dec 2025; status: recruiting.
02
Drugs
rebonuputemcel
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT07254806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254806.